Drug Trial Radar · NCT07924930
A Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney Function
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to measure how much tersolisib gets into the bloodstream and how long it takes the body to eliminate it in participants with kidney impairment compared to those with normal kidney function. The safety of tersolisib will also be evaluated. For each participant, the study will last about 7 weeks including a 14-night stay in the clinical research unit (CRU) and one follow-up telephone call.
Conditions
- Renal Insufficiency
- Healthy Participant
Interventions
TersolisibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of TersolisibTime frame: Predose on Day 1 through Day 14
- PK: Area Under the Concentration Versus Time Curve (AUC) of TersolisibTime frame: Predose on Day 1 through Day 14
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Omega Research Orlando
Altamonte Springs, Florida
Floridian Clinical Research
Miami Lakes, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.